You are viewing the site in preview mode
Skip to main content
|
Parameters
|
Tofogliflozin group (n = 80)
|
Conventional group (n = 74)
|
p value
|
|---|
|
Sex (males) (%)
|
48 (60.0)
|
48 (64.9)
|
0.53
|
|
Age (years)
|
61.5 ± 9.2
|
62.5 ± 9.3
|
0.50
|
|
Current smoking
|
16 (20.0)
|
14 (18.9)
|
0.87
|
|
Body mass index (kg/m2)
|
26.4 ± 5.4
|
26.2 ± 4.2
|
0.83
|
|
Waist circumference (cm)
|
91.2 ± 12.3 (n = 75)
|
91.7 ± 10.7
|
0.79
|
|
Duration of diabetes (years)
|
11.9 ± 8.2
|
14.1 ± 8.7
|
0.11
|
|
HbA1c (%)
|
7.5 ± 0.7
|
7.4 ± 0.8
|
0.32
|
|
Fasting blood glucose (mmol/L)
|
8.0 ± 1.8
|
7.9 ± 1.8 (n = 73)
|
0.65
|
|
C-peptide (ng/mL)
|
1.91 ± 1.11 (n = 79)
|
1.92 ± 0.89 (n = 73)
|
0.96
|
|
Hypertension
|
38 (47.5)
|
49 (66.2)
|
0.019
|
|
Systolic blood pressure (mmHg)
|
130.9 ± 14.4
|
132.4 ± 18.8
|
0.58
|
|
Diastolic blood pressure (mmHg)
|
79.0 ± 10.0
|
79.6 ± 12.0
|
0.70
|
|
Dyslipidemia
|
48 (60.0)
|
51 (68.9)
|
0.31
|
|
Total cholesterol (mmol/L)
|
5.01 ± 0.77 (n = 79)
|
5.07 ± 0.79 (n = 73)
|
0.63
|
|
LDL cholesterol (mmol/L)
|
2.88 ± 0.69
|
3.01 ± 0.66
|
0.25
|
|
HDL cholesterol (mmol/L)
|
1.47 ± 0.39
|
1.37 ± 0.27
|
0.09
|
|
Triglyceride (mmol/L)
|
1.07 [0.84, 1.61]
|
1.46 (1.02, 1.90)
|
0.011
|
|
Diabetic retinopathy
|
14 (17.9)
|
17 (23.3)
|
0.43
|
|
eGFR (mL/min/1.73 m2)
|
79.1 ± 19.9
|
82.0 ± 26.6
|
0.45
|
|
Urinary albumin excretion (mg/g/cre)
|
9.6 (5.7, 36.8) (n = 75)
|
18.7 (5.3, 65.9) (n = 69)
|
0.38
|
|
Diabetic nephropathy
|
24 (30.0)
|
27 (36.5)
|
0.49
|
|
Use of glucose-lowering agents
|
69 (86.3)
|
61 (82.4)
|
0.66
|
|
Metformin
|
36 (45.0)
|
38 (51.4)
|
0.52
|
|
Sulfonylurea
|
16 (20.0)
|
14 (18.9)
|
1.00
|
|
Glinides
|
4 (5.0)
|
4 (5.4)
|
1.00
|
|
Thiazolidinediones
|
8 (10.0)
|
10 (13.5)
|
0.62
|
|
α-Glucosidase inhibitor
|
14 (17.5)
|
15 (20.3)
|
0.68
|
|
DPP-4 inhibitors
|
36 (45.0)
|
34 (45.9)
|
1.00
|
|
GLP-1 R agonists
|
9 (11.3)
|
4 (5.4)
|
0.25
|
|
Insulin
|
12 (15.0)
|
16 (21.6)
|
0.30
|
|
Use of antihypertensive drugs
|
36 (45.0)
|
46 (62.2)
|
0.037
|
|
Angiotensin-converting enzyme inhibitors
|
1 (1.3)
|
4 (5.4)
|
0.20
|
|
Angiotensin II receptor blockers
|
25 (31.3)
|
41 (55.4)
|
0.003
|
|
Direct renin inhibitor
|
1 (1.3)
|
0 (0.0)
|
1.00
|
|
Calcium channel blocker
|
24 (30.0)
|
24 (32.4)
|
0.86
|
|
Diuretic drugs
|
4 (5.0)
|
6 (8.1)
|
0.52
|
|
α-Adrenergic receptor antagonist
|
1 (1.3)
|
0 (0.0)
|
1.00
|
|
β-Adrenergic receptor antagonist
|
3 (3.8)
|
2 (2.7)
|
1.00
|
|
Others
|
0 (0.0)
|
0 (0.0)
|
–
|
|
Use of lipid-lowering agents
|
39 (48.8)
|
39 (52.7)
|
0.63
|
|
Statins
|
33 (41.3)
|
32 (42.3)
|
0.87
|
|
Ezetimibe
|
4 (5.0)
|
5 (6.8)
|
0.74
|
|
Resins
|
0 (0.0)
|
0 (0.0)
|
–
|
|
Fibrates
|
4 (5.0)
|
2 (2.7)
|
0.68
|
|
Use of antithrombotic agents
|
11 (13.8)
|
11 (14.9)
|
1.00
|
|
Antiplatelet agents
|
10 (12.5)
|
9 (12.2)
|
1.00
|
|
Anticoagulants
|
1 (1.3)
|
2 (2.7)
|
0.61
|
|
Others
|
0 (0.0)
|
0 (0.0)
|
–
|
|
Right baPWV (cm/s)
|
1690.1 ± 399.2
|
1680.4 ± 323.6
|
0.87
|
|
Left baPWV (cm/s)
|
1696.2 ± 432.7
|
1672.8 ± 338.0
|
0.71
|
|
Mean baPWV (cm/s)
|
1693.2 ± 410.3
|
1676.6 ± 324.6
|
0.78
|
- Data are presented as the number (%) of patients, mean ± standard deviation (SD) values, or median (the 25th and 75th percentiles) values
- HbA1C glycated hemoglobin, SD standard deviation, LDL low-density lipoprotein, HDL high-density lipoprotein, DPP-4 dipeptidyl peptidase, GLP glucagon-like peptide-1, baPWV brachial-ankle pulse wave velocity
